Updated results from a phase II study of perioperative disitamab vedotin (RC48-ADC) plus cadonilimab (AK104, PD-1CTLA-4 bispecific antibody) for HER2-expressing muscle-invasive bladder cancer (MIBC).
How low do you need to go? Association between various prostate-specific antigen (PSA) response measures and clinical outcomes in metastatic castration‑sensitive prostate cancer (mCSPC) in the Veteran Health Administration (VHA) data